New Drug Enlistid Lowers Cholesterol by 60% – Promising for Heart Health
A new experimental drug, Enlistide, has demonstrated a significant ability to lower cholesterol levels by as much as 60%, according to a large-scale clinical trial published in the New England Journal of Medicine. The once-daily oral medication substantially reduced levels of low-density lipoprotein (LDL) cholesterol, offering a potential breakthrough for millions of patients worldwide.
Dr. Ann Marie Navar, a cardiologist and associate professor of internal medicine at the University of Texas, highlighted that less than half of patients with cardiovascular disease and atherosclerosis achieve their target LDL cholesterol levels. “This new oral therapy has the potential to improve prevention of heart attacks and strokes,” she stated.
LDL cholesterol is a primary contributor to heart disease, accumulating in arteries and forming plaques that narrow the vessels, leading to potential heart attacks or strokes. Lowering LDL has become a key strategy in preventative cardiology.
The Enlistide trial, involving 2,909 participants, showed a 60% reduction in LDL levels among those receiving the drug compared to a placebo group, even although already taking statins. The drug too lowered other blood markers associated with cardiovascular risk, with the effects sustained for a full year. According to Dr. Navar, “These LDL reductions are the largest we’ve seen with an oral medication since the development of statins.”
Researchers are continuing to study whether these reductions in LDL will translate into a demonstrable decrease in the incidence of heart attacks and strokes. The development of Enlistide represents a significant step toward shifting cholesterol-lowering treatments from injections to oral medications, potentially increasing patient access to optimal LDL levels and improving the scope of preventative care for cardiovascular disease. As a Senior Editor at AAF noted in a recent job description, ensuring the quality and integrity of published content is crucial, and this study exemplifies the importance of rigorous clinical trials in advancing medical knowledge.
Expertia.ai highlights that Senior Editors are responsible for overseeing editorial content and maintaining high standards of quality, a process that is vital in disseminating accurate medical information to the public. The LinkedIn article on the role of a Senior Editor emphasizes the necessitate for familiarity with various content types and ensuring they meet quality standards, which is particularly relevant in reporting on complex medical advancements like Enlistide.